Fisher Asset Management LLC Reduces Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Fisher Asset Management LLC decreased its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 4.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 3,182,617 shares of the biotechnology company’s stock after selling 155,445 shares during the period. Fisher Asset Management LLC’s holdings in BioCryst Pharmaceuticals were worth $23,933,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC purchased a new stake in BioCryst Pharmaceuticals during the 4th quarter worth $46,000. R Squared Ltd bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth about $48,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,322 shares during the last quarter. KBC Group NV increased its position in shares of BioCryst Pharmaceuticals by 80.1% in the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 4,537 shares during the last quarter. Finally, Quantinno Capital Management LP bought a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter worth about $82,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

NASDAQ BCRX opened at $8.54 on Tuesday. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $9.50. The company has a 50-day simple moving average of $8.11 and a 200-day simple moving average of $7.86. The firm has a market capitalization of $1.78 billion, a PE ratio of -14.00 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analysts’ expectations of $126.64 million. The firm’s revenue for the quarter was up 40.8% compared to the same quarter last year. During the same period last year, the firm earned $0.28 earnings per share. Equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on BCRX shares. Needham & Company LLC boosted their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Wedbush started coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 target price for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $11.00 target price (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Finally, Barclays lifted their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $15.57.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.